DNA methylation in oral squamous cell carcinoma: from its role in carcinogenesis to potential inhibitor drugs

Crit Rev Oncol Hematol. 2021 Aug:164:103399. doi: 10.1016/j.critrevonc.2021.103399. Epub 2021 Jun 17.

Abstract

DNA methylation is one of epigenetic changes most frequently studied nowadays, together with its relationship with oral carcinogenesis. A group of enzymes is responsible for methylation process, known as DNA methyltransferases (DNMT). Although essential during embryogenesis, DNA methylation pattern alterations, including global hypomethylation or gene promoter hypermethylation, can be respectively associated with chromosomal instability and tumor suppressor gene silencing. Higher expression of DNA methyltransferases is a common finding in oral cancer and may contribute to inactivation of important tumor suppressor genes, influencing development, progression, metastasis, and prognosis of the tumor. To control these alterations, inhibitor drugs have been developed as a way to regulate DNMT overexpression, and they are intended to be associated with ongoing chemo- and radiotherapy in oral cancer treatments. In this article, we aimed to highlight the current knowledge about DNA methylation in oral cancer, including main hyper/hypomethylated genes, DNMT expression and its inhibitor treatments.

Keywords: DNA Methylation; Epigenomics; Methyltransferases; Mouth Neoplasms; Oral Cancer; Squamous Cell Carcinoma.

Publication types

  • Review

MeSH terms

  • Carcinogenesis / genetics
  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / genetics
  • DNA Methylation
  • Gene Expression Regulation, Neoplastic
  • Head and Neck Neoplasms*
  • Humans
  • Mouth Neoplasms* / drug therapy
  • Mouth Neoplasms* / genetics
  • Pharmaceutical Preparations*
  • Squamous Cell Carcinoma of Head and Neck

Substances

  • Pharmaceutical Preparations